BioCentury
ARTICLE | Clinical News

EBV-CTL regulatory update

April 6, 2015 7:00 AM UTC

Atara Biotherapeutics Inc. (NASDAQ:ATRA, Brisbane, Calif.) said FDA granted breakthrough therapy designation to EBV-CTL from Memorial Sloan Kettering Cancer Center to treat rituximab-refractory lymph...